Published in J Nucl Med on January 01, 1995
New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) (2009) 1.92
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging (2011) 1.89
Imaging of pheochromocytoma and paraganglioma. Fam Cancer (2005) 1.49
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med (2008) 1.12
Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging (2012) 0.91
Current concepts in the management of adrenal incidentalomas. Urol Ann (2012) 0.89
Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging (2010) 0.85
Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg (2011) 0.83
Diagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma. Nucl Med Mol Imaging (2015) 0.81
The biology and clinical relevance of somatostatin receptor scintigraphy in adrenal tumor management. Yale J Biol Med (1999) 0.77
Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT. World J Radiol (2010) 0.75
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer (1998) 2.57
Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer (1988) 2.46
CD44 contributes to T cell activation. J Immunol (1989) 2.44
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet (2001) 2.28
Second primary malignancies in thyroid cancer patients. Br J Cancer (2003) 2.10
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab (2000) 1.96
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene (1997) 1.91
The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma. Ann Intern Med (1996) 1.87
Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med (1996) 1.77
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab (1999) 1.67
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol (2004) 1.63
Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol (1987) 1.60
Cardiac pheochromocytomas. Ann Thorac Surg (1992) 1.55
Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol (2004) 1.52
Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. J Clin Endocrinol Metab (1997) 1.52
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer (2004) 1.52
Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol (1999) 1.51
The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab (1995) 1.49
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med (1996) 1.49
ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene (2011) 1.45
[112 cases of sporadic and genetically determined pheochromocytoma: a comparative pathologic study]. Ann Pathol (1999) 1.44
Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison. J Am Coll Cardiol (1990) 1.43
Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res (2000) 1.43
Presence of mutations in all three ras genes in human thyroid tumors. Oncogene (1990) 1.42
Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) (2010) 1.41
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res (1993) 1.41
Evidence of increased chromosomal abnormalities in French Polynesian thyroid cancer patients. Eur J Nucl Med Mol Imaging (2004) 1.39
[Unusual site of an embryonal rhabdomyosarcoma of the mesenchymal hepatic pedicle]. Ann Pathol (1999) 1.39
Renin secreting tumors: diagnosis, conservative surgical approach and long-term results. J Urol (1995) 1.39
Haematopoietic growth factors in the treatment of therapeutic and accidental irradiation-induced bone marrow aplasia. Int J Radiat Biol (1995) 1.38
gsp mutations in human thyroid tumours. Oncogene (1991) 1.37
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer (2011) 1.36
RET mutations in exons 13 and 14 of FMTC patients. Oncogene (1995) 1.35
Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res (1993) 1.31
Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res (2001) 1.30
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer (2001) 1.30
Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol (1984) 1.30
External radiotherapy in thyroid cancers. Cancer (1985) 1.28
Benefits of a computer-assisted education program for hypertensive patients compared with standard education tools. Patient Educ Couns (1995) 1.27
Two-subunit structure of the human thyrotropin receptor. Proc Natl Acad Sci U S A (1992) 1.26
gamma-Glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system. Free Radic Biol Med (1998) 1.26
Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. Br Med J (Clin Res Ed) (1982) 1.25
Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab (1997) 1.25
Treatment of malignant pheochromocytoma. Horm Metab Res (2009) 1.25
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer (1998) 1.23
Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant (1999) 1.23
[Screening for phaeochromocytoma : in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's transl)]. Nouv Presse Med (1981) 1.22
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab (2011) 1.20
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer (2001) 1.19
Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab (1998) 1.18
Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol (2010) 1.18
Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet (1997) 1.16
Expression of pendrin and the Pendred syndrome (PDS) gene in human thyroid tissues. J Clin Endocrinol Metab (2000) 1.15
Study of a virus-induced myeloproliferative syndrome associated with tumor formation in mice. Eur J Cancer (1980) 1.14
Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab (2012) 1.13
Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med (2000) 1.13
Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab (1997) 1.12
Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene (1988) 1.12
Do patients with low tension glaucoma have particular cardiovascular characteristics? Ophthalmologica (1984) 1.11
Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab (2005) 1.11
Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. J Clin Endocrinol Metab (2010) 1.11
Expression of Na+/I- symporter and Pendred syndrome genes in trophoblast cells. J Clin Endocrinol Metab (2000) 1.10
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab (2003) 1.10
Possible familial origin of multifocal renal artery fibromuscular dysplasia. J Hypertens (1997) 1.09
Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab (1998) 1.08